Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) went down by -0.39% from its latest closing price when compared to the 1-year high value of $64.48 and move down -19.81%, while ARNA stocks collected +7.06% of gains with the last five trading sessions. Press Release reported on 02/11/20 that Arena Pharmaceuticals’ Presence at the European Crohn’s and Colitis Organisation (ECCO) Congress Further Highlights Commitment to the GI Community
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Worth an Investment?
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) scored price to earnings ratio above its average ratio, recording 4.99 times of increase in earnings at the present.
ARNA Market Performance
ARNA stocks went up by 7.06% for the week, with the monthly jump of 17.85% and a quarterly performance of 16.57%, while its annual performance rate touched 11.08%. The simple moving average for the period of the last 20 days is 13.69% for ARNA stocks with the simple moving average of 4.49% for the last 200 days.
Analysts’ Opinion on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Many brokerage firms have already submitted their reports for ARNA stocks, with JP Morgan repeating the rating for ARNA shares by setting it to “Overweight”. The predicted price for ARNA socks in the upcoming period according to JP Morgan is $58 based on the research report published on January 31, 2020.
BofA/Merrill, on the other hand, stated in their research note that they expect to see ARNA stock at the price of $51. The rating they have provided for ARNA stocks is “Neutral” according to the report published on November 13, 2019.
Berenberg gave “Buy” rating to ARNA stocks, setting the target price at $55 in the report published on December 13, 2018.
ARNA Stocks 14.95% Far from 50 Day Moving Average
After a stumble in the market that brought ARNA to its low price for the period of the last 52 weeks, Arena Pharmaceuticals, Inc. was unable to take a rebound, for now settling with -16.53% of loss for the given period.
The stock volatility was left at 3.66%, however, within the period of a single month, the volatility rate increased by 5.85%, while the shares surge at the distance of +19.10% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +16.29% upper at the present time.
In the course of the last 5 trading sessions, ARNA went up by +7.06%, which changed the moving average for the period of 200 days to the total of +17.64% of gains for the stock in comparison to the 20-day moving average settled at $47.77. In addition, Arena Pharmaceuticals, Inc. saw 18.49% in overturn over the period of a single year with a tendency to cut further gains.
ARNA Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Arena Pharmaceuticals, Inc. (ARNA), starting from Aurentz Vincent, who sold 9,000 shares at the price of $50.00 back on Feb 05. After this action, Rushing now owns 0 shares of Arena Pharmaceuticals, Inc., valued at $450,000 with the latest closing price.
Munshi Amit, the President and CEO of Arena Pharmaceuticals, Inc., sold 7,129 shares at the value of $50.00 during a trade that took place back on Feb 05, which means that Munshi Amit is holding 7,750 shares at the value of $356,450 based on the most recent closing price.
ARNA Stock Fundamentals
The current profitability levels are settled at -805.69 for the present operating margin. The net margin for Arena Pharmaceuticals, Inc. stands at -158.98. Total capital return value is set at -31.21, while invested capital returns managed to touch -6.21. Equity return holds the value 52.90%, with 48.80% for asset returns.
Based on Arena Pharmaceuticals, Inc. (ARNA), the company’s capital structure generated 8.69 points for debt to equity in total, while total debt to capital is set at the value of 8.00. Total debt to assets is settled at the value of 7.67 with long-term debt to equity ratio rests at -25.42 and long-term debt to capital is 8.15.
The value for Enterprise to Sales is 2.34 with debt to enterprise value settled at 0.04. The receivables turnover for Arena Pharmaceuticals, Inc. is 1.85 with the total asset turnover at the value of 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.40.